Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution
News Oct 15, 2010
The Tecan Group and Luminex Corporation have announced that they will collaborate on the development of a new automated newborn screening solution that will provide faster results for infants' potential health concerns.
The companies have entered into a global OEM agreement that allows them to combine Luminex® xMAP® technology and LX 200™ instrument with Tecan's flexible and reliable Freedom EVO® liquid handling platform and HydroFlex™ washer. The new automated newborn screening solution will help laboratories enhance efficiency, save vital resources and analyze more samples. Luminex expects to launch the automated newborn screening solution in 2011.
Thomas Bachmann, CEO of Tecan, said: "We are delighted that we have been chosen by Luminex to supply a fully automated solution for such an important application. This global OEM agreement is building on a long, well established partnership of creating the most advanced automated solutions in the research market for Luminex xMAP technology."
Luminex xMAP technology enables large numbers of biological tests to be conducted simultaneously and analyzed quickly. Once it receives regulatory clearance, NeoPlex4™ will be a fully automated, walk-away testing platform for multiplexed newborn screening. These high-volume screening assays test newborn infants for several different biomarkers linked to critical diseases.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Introduction to Metabolomics Analysis
Mar 20 - Mar 23, 2018